Regenicin

Shares of Regenicin are expected to continue to increase as the micro-cap business plans to start the commercialisation of the US Food and Drug Administration (FDA) approved orphan product skin substitute for burn victims. Shareholders pushed the shares 76.47% higher from $0.13 a share to $0.27 on Tuesday and increased even more after hours, after